Latest News from "The Pink Sheet" DAILY

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.   read more

 

Newly-Funded Receptos Bets On The Safety Of Its Oral MS Drug

Privately held San Diego firm is staked with $25 million in a Series A involving four VC investors.   read more

 

GSK Temporarily Pulls sNDA For Avodart

GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.   read more

 

BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability

New claim puts the atypical antipsychotic on par with J&J's Risperdal.   read more

 

Health Reform Taxes: Senate Reduces Device Fee, Adds Cosmetic Surgery Tax

The consolidated Senate bill, which will be taken up for debate on the floor next week, includes a $2 billion-per-year, 10-year annual fee on device manufacturers and importers.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here